Economic assessment of home-based COPD management programs

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 10, Issue 6, 2013, Pages 640-649

  Liu, Sheena Xin ^a   Lee, Michael C ^a   Atakhorrami, Maryam ^a   Tatousek, Jan ^a   McCormack, Meredith ^b   Yung, Rex ^b   Hart, Nicholas ^c   White, David P ^d  

^a PHILIPS RESEARCH LABORATORIES   (Netherlands)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE EXACERBATION; EARLY DIAGNOSIS; HEALTH PROGRAM; HOME CARE; HOME MONITORING; HOSPITALIZATION; LENGTH OF STAY; MONTE CARLO METHOD; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; SIMULATION; TELEHEALTH;

COST SAVINGS; DISEASE MANAGEMENT; HEALTH CARE COSTS; HOME CARE SERVICES; HOSPITALIZATION; HUMANS; MARKOV CHAINS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY-ADJUSTED LIFE YEARS; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TELEMEDICINE;

EID: 84887933227     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.3109/15412555.2013.813447     Document Type: Article

References (41)

1. Sullivan SD, Ramsey SD, Lee TA. The economic burden of COPD. Chest 2000; 117(2 Suppl):5S-9S.
2. National Institutes of Health National Heart Lung and Blo od Institute Morbidity &Mortality: Chart Book on Cardio vascular, Lung, and Blood Diseases. 2009 [cited 2013 March 1, 2013]; Available from: http://www.nhlbi.nih. gov/resources/docs/chtbook. htm.
3. Simoens S. The economic burden of COPD exacerbations. COPD, 2010; 7(3):159-61.
4. Andersson F, et al. The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir Med 2002; 96(9):700-8.
5. Seemungal TA, et al. Eff ect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157(5 Pt 1):1418-22.
6. Menn PN, Weber, Holle R. Health-related quality of life in patients with severe COPD hospitalized for exacerbations - comparing EQ-5D, SF-12 and SGRQ. Health Qual Life Outcomes 2010; 8:39.
7. Hurst JR, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010. 363(12): p. 1128-38.
8. Bourbeau J. Disease management for COPD: avoiding hospitalizations and controlling cost? COPD 2011; 8(3):143-144.
9. Newhouse JP. Financing Medicare in the next administration. N Engl J Med 2004; 351(17):1714-6.
10. Neumann PJ, Rosen AB, Weinstein MC. Medicare and costeff ectiveness analysis. N Engl J Med 2005; 353(14): 1516-22.
11. Warren PM, et al. Respiratory failure revisited: acute exacerbations of chronic bronchitis between 1961-68 and 1970-76. Lancet 1980; 1(8166):467-70.
12. Connors AF Jr, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med, 1996; 154(4 Pt 1):959-67.
13. Hoogendoorn M, et al. Association between lung function and exacerbation frequency in patients with COPD. Int J Chron Obstruct Pulmon Dis 2010; 5:435-44.
14. Halpin DM. HealTheconomics of chronic obstructive pulmonary disease. Proc Am Th orac Soc, 2006; 3(3): 227-33.
15. Rutten-van Molken M, Lee TA. Economic modeling in chronic obstructive pulmonary disease. Proc Am Th orac Soc, 2006; 3(7):630-4.
16. Seemungal TA, et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 2000; 161(5):1608-13.
17. Fuso L, et al. Predicting mortality of patients hospitalized for acutely exacerbated chronic obstructive pulmonary disease. Am J Med, 1995; 98(3):272-7.
18. Atsou K, Chouaid C, Hejblum G. Simulation-based estimates of eff ectiveness and cost-eff ectiveness of smoking cessation in patients with chronic obstructive pulmonary disease. PLoS One 2011; 6(9):e24870.
19. Oostenbrink JB, et al. Probabilistic markov model to assess the cost-eff ectiveness of bronchodilator therapy in COPD patients in diff erent countries. Value in Health 2005; 8(1): 32-46.
20. Dalal AA, et al. Direct costs of chronic obstructive pulmonary disease among managed care patients. Int J Chron Obstruct Pulmon Dis 2010; 5:341-9.
21. Yu AP, et al. Incremental third-party costs associated with COPD exacerbations: a retrospective claims analysis. J Med Econ 2011; 14(3):315-23.
22. Borg S, et al. A computer simulation model of the natural history and economic impact of chronic obstructive pulmonary disease. Value Health, 2004; 7(2):153-67.
23. Mittmann N, et al. The cost of moderate and severe COPD exacerbations to the Canadian healthcare system. Respir Med, 2008; 102(3):413-21.
24. Paterson C, et al. Assessing patient outcomes in acute exacerbations of chronic bronchitis: the measure your medical outcome profi le (MYMOP), medical outcomes study 6-item general health survey (MOS-6A) and EuroQol (EQ-5D). Qual Life Res 2000; 9(5):521-7.
25. Dalal AA, et al. Costs of COPD exacerbations in the emergency department and inpatient setting. Respir Med 2011; 105(3):454-60.
26. Stanford RH, Shen Y, McLaughlin T. Cost of Chronic Obstructive Pulmonary Disease in the Emergency Department and Hospital: An Analysis of Administrative Data from 218 US Hospitals. Treat Respir Med, 2006; 5(5):343-9.
27. Spencer S, Jones PW. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Th orax, 2003; 58(7):589-93.
28. National Institute for Health and Clinical Excellence: Guide to the methods of technology appraisal. [cited 2011; Available from: http://www.nice.org.uk/aboutnice/howwework/devnicetech/ technologyappraisalprocessguides/guidetothemethodsoftechnologyappraisal.jsp
29. Siegel J, et al. Guidelines for Pharmacoeconomic Studies. PharmacoEconomics, 1997; 11(2):159-168.
30. Lewis KE, et al. Home telemonitoring and quality of life in stable, optimised chronic obstructive pulmonary disease. J Telemed Telecare, 2010; 16(5):253-9.
31. Lewis KE, et al. Does home telemonitoring after pulmonary rehabilitation reduce healthcare use in optimized COPD? A pilot randomized trial. COPD, 2010; 7(1):44-50.
32. Hanna B. Evaluation Report for COPD Telehealth Project. 2008.
33. McLean S, et al. Telehealthcare for chronic obstructive pulmonary disease: Cochrane Review and meta-Analysis. Br J Gen Pract. 62(604):e739-49.
34. Mapel DW, et al. A new method for examining the cost savings of reducing COPD exacerbations. Pharmacoeconomics. 28(9): 733-49.
35. Ijzerman MJ, Steuten LM. Early assessment of medical technologies to inform product development and market access: a review of methods and applications. Appl HealThecon Health Policy. 9(5):331-47.
36. Girling, AJ, Lilford RJ, Young TP. Pricing of medical devices under coverage uncertainty-A modelling approach. HealThecon. 21(12):1502-7.
37. Ginsburg ME. Cost-eff ectiveness: will the public buy it or balk? Health Aff (Millwood), 2004. Suppl Web Exclusives: p. W4-297-9.
38. Bloom BS. Use of formal benefi t/cost evaluations in health system decision making. Am J Manag Care, 2004; 10(5): 329-35.
39. Statement for Ways and Means hearing to examine comparative eff ectiveness. 2007 [cited 2011; Available from: www.bcbs.com/news/bcbsa/statement- on-ways-Andmeans- hearing-to-examine-comparative-effectivenessresearch. html.
40. Vallejo-Torres L, et al. Integrating healTheconomics into the product development cycle: a case study of absorbable pins for treating hallux valgus. Med Decis Making, 2011; 31(4): 596-610.
41. Ijzerman MJ, Steuten LM. Early assessment of medical technologies to inform product development and market access: a review of methods and applications. Appl HealThecon Health Policy, 2011; 9(5):331-47.